Ezra Cohen: Benefit of adding cetuximab adjuvantly was seen only in HPV negative cancers
Ezra Cohen, Chief Medical Officer of Oncology at Tempus Labs, posted LinkedIn about recent paper by Mitchell Machtay et al., titled “Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer” published on Journal of Clinical Oncology.
Authors: Mitchell Machtay, Pedro A. Torres-Saavedra, Wade Thorstad, Phuc Felix Nguyen-Tân, Lillian L. Siu, F. Christopher Holsinger, Adel El-Naggar, Christine Chung, Anthony Cmelak, Barbara Burtness, Greg Bednarz, Harry Quon, Stephen L. Breen, Clement K. Gwede, Adam P. Dicker, Min Yao, Richard C. Jordan, Jennifer Dorth, Nancy Lee, Jason W. Chan, Neal Dunlap, Voichita Bar-Ad, William A. Stokes, Arnab Chakravarti, David Sher, Shyam Rao, Jonathan Harris, Sue S. Yom, Quynh-Thu Le
“Benefit of adding cetuximab adjuvantly was seen only in HPV negative cancers – ~10% absolute improvement in DFS and OS. Efforts should be directed at finding which HPV negative cancers benefit from EGFR inhibition.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023